Akela Pharma Inc. Completes Share Consolidation



    www.akelapharma.com
    Toronto Stock Exchange Symbol: AKL

    MONTREAL, Oct. 9 /CNW Telbec/ - AKELA Pharma Inc., (TSX: AKL), a drug
development company focused on developing therapies for the inhalation, pain
and CNS markets, today announced that effective October 10, 2007, its issued
and outstanding common shares will be consolidated on the basis of one (1)
post-consolidation common share for every seven (7) pre-consolidation common
shares. Fractional interests will be paid in cash in U.S. dollars for
shareholders other than those in Canada who will be paid in Canadian dollars.
The common shares will commence trading on the Toronto Stock Exchange on a
post-consolidated basis at the opening of trading on October 10, 2007.
    The share consolidation has been effected to satisfy the NASDAQ's listing
criteria regarding minimum bid price. After the share consolidation, the
Company will have approximately 11.75 million common shares outstanding. The
stock symbol of the Company will remain AKL on the TSX.

    About Akela Pharma Inc.

    Akela Pharma is an integrated drug development company focused on
developing therapies for the growing multi-billion dollar inhalation, pain and
CNS markets. Its lead product, for the treatment of breakthrough cancer pain,
is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R)
dry powder inhaler platform. Its pipeline also includes therapeutics for
asthma, COPD, growth hormone deficiencies and controlled substance abuse
deterrent formulations.
    Akela's common shares trade on The Toronto Stock Exchange ("TSX") under
the symbol "AKL" with 82.3 million shares outstanding.
    This news release contains certain forward-looking statements that
reflect the current views and/or expectations of AKELA Pharma Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
    %SEDAR: 00003466EF




For further information:

For further information: visit Akela's website at www.akelapharma.com,
or contact: Frédéric Dumais, Vice-President, Investor Relations, (514)
315-3330 ext. 106, Fax: (514) 315-3325; Tina Posterli (U.S. Media), (917)
322-2565, tposterli@rxir.com

Organization Profile

Akela Pharma Inc

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890